Paper36924120
The clinical management of hepatocellular carcinoma in China: Progress and challenges.
Shan S and 1 other. Clin Mol Hepatol, 2023. Cited by 21 papers, by iCite.
Cite this record
ConductScience Library. The clinical management of hepatocellular carcinoma in China: Progress and challenges. Papers, record 36924120. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36924120
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Humans | |
| East Asian People | |
| China |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82000569 | National Natural Science Foundation of China | PubMed | ||
| 82270603 | National Natural Science Foundation of China | PubMed |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment on | 36545708 | Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective. | https://conductscience.org/library/papers/36545708 |
Source PubMed
References23
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32963466 | A study protocol of population-based cancer screening cohort study on esophageal, stomach and liver cancer in rural China. | Chin J Cancer Res | 2020 | https://conductscience.org/library/papers/32963466 | PubMed |
| 2 | 30404026 | Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. | Gastroenterology | 2019 | https://conductscience.org/library/papers/30404026 | PubMed |
| 3 | 34846705 | Consensus on the secondary prevention of primary liver cancer. | Hepatol Int | 2021 | https://conductscience.org/library/papers/34846705 | PubMed |
| 4 | 34805067 | Disparities in Hepatocellular Carcinoma Survival by Insurance Status: A Population-Based Study in China. | Front Public Health | 2021 | https://conductscience.org/library/papers/34805067 | PubMed |
| 5 | 30143694 | Mass screening for liver cancer: results from a demonstration screening project in Zhongshan City, China. | Sci Rep | 2018 | https://conductscience.org/library/papers/30143694 | PubMed |
| 6 | 31385465 | Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China. | Cancer Med | 2019 | https://conductscience.org/library/papers/31385465 | PubMed |
| 7 | 35800051 | Epidemiological Characteristics of Primary Liver Cancer in Mainland China From 2003 to 2020: A Representative Multicenter Study. | Front Oncol | 2022 | https://conductscience.org/library/papers/35800051 | PubMed |
| 8 | 34823308 | The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection. | Clin Mol Hepatol | 2022 | https://conductscience.org/library/papers/34823308 | PubMed |
| 9 | 36304493 | Management Algorithm for Prevention of Mother-to-child Transmission of Hepatitis B Virus (2022). | J Clin Transl Hepatol | 2022 | https://conductscience.org/library/papers/36304493 | PubMed |
| 10 | 15042359 | Randomized controlled trial of screening for hepatocellular carcinoma. | J Cancer Res Clin Oncol | 2004 | https://conductscience.org/library/papers/15042359 | PubMed |
| 11 | 9222303 | Prospective study of early detection for primary liver cancer. | J Cancer Res Clin Oncol | 1997 | https://conductscience.org/library/papers/9222303 | PubMed |
| 12 | 36545708 | Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective. | Clin Mol Hepatol | 2023 | https://conductscience.org/library/papers/36545708 | PubMed |
| 13 | 33317248 | Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects. | Clin Mol Hepatol | 2021 | https://conductscience.org/library/papers/33317248 | PubMed |
| 14 | 36207940 | [The consensus on tertiary prevention of primary liver cancer (2022 version)]. | Zhonghua Gan Zang Bing Za Zhi | 2022 | https://conductscience.org/library/papers/36207940 | PubMed |
| 15 | 36263667 | Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease. | Clin Mol Hepatol | 2022 | https://conductscience.org/library/papers/36263667 | PubMed |
| 16 | 36764320 | Global reporting of progress towards elimination of hepatitis B and hepatitis C. | Lancet Gastroenterol Hepatol | 2023 | https://conductscience.org/library/papers/36764320 | PubMed |
| 17 | 34590058 | Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China. | Lancet Reg Health West Pac | 2021 | https://conductscience.org/library/papers/34590058 | PubMed |
| 18 | 30605974 | [Strategies of primary prevention of liver cancer in China: expert consensus (2018)]. | Zhonghua Yu Fang Yi Xue Za Zhi | 2019 | https://conductscience.org/library/papers/30605974 | PubMed |
| 19 | 31283409 | Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/31283409 | PubMed |
| 20 | 25549238 | Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. | PLoS Med | 2014 | https://conductscience.org/library/papers/25549238 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42953582 | Psychological Stress in Hepatocellular Carcinoma: Clinical Outcomes and Biological Mechanisms. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42953582 | PubMed |
| 42757287 | Bibliometric Analysis of Gut Microbiota and Hepatocellular Carcinoma: Research Trends and Frontiers. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42757287 | PubMed |
| 42703451 | Application value of dual-phase cone-beam computed tomography during hepatic arteriography in the detection of ≤2 cm hypervascular hepatocellular carcinoma and its feeding arteries. | J Gastrointest Oncol | 2026 | https://conductscience.org/library/papers/42703451 | PubMed |
| 42703324 | Hepatic arterial infusion or intravenous infusion of adebrelimab, combined with bevacizumab and HAIC of the FOLFOX regimen for advanced unresectable hepatocellular carcinoma (HAIBrave-001 trial): a study protocol of a prospective, double-arm, phase II trial. | J Gastrointest Oncol | 2026 | https://conductscience.org/library/papers/42703324 | PubMed |
| 42384246 | CNOT9 affects hepatocellular carcinoma proliferation and cell cycle through the PTEN/AKT/p53 signaling pathway. | Hum Cell | 2026 | https://conductscience.org/library/papers/42384246 | PubMed |
| 42181737 | ENPP2 Dysregulation Defines a Candidate Biomarker Axis Coupling Tumor-Intrinsic cAMP Signaling to Macrophage Polarization in Hepatocellular Carcinoma. | Hum Mutat | 2026 | https://conductscience.org/library/papers/42181737 | PubMed |
| 41403946 | LASSO-empowered nomogram integrating nutritional-inflammatory-tumor characteristics predicts immunotherapy outcomes in advanced HCC: Large retrospective cohort. | Front Immunol | 2025 | https://conductscience.org/library/papers/41403946 | PubMed |
| 41368427 | Effect of External Oblique Intercostal Block on Postoperative Analgesia and Early Recovery in Patients Undergoing Open Liver Resection for Hepatocellular Carcinoma or Intrahepatic Bile Duct Stones: A Randomized Controlled Clinical Trial. | Local Reg Anesth | 2025 | https://conductscience.org/library/papers/41368427 | PubMed |
| 41237121 | MRI-based 2.5D deep learning and radiomics effectively predicted microvascular invasion and Ki-67 expression in hepatocellular carcinoma. | PLoS One | 2025 | https://conductscience.org/library/papers/41237121 | PubMed |
| 41026296 | Long noncoding RNA RHPN1-AS1 promotes hepatocellular carcinoma progression under hypoxia through interaction with RPS15A protein. | Med Oncol | 2025 | https://conductscience.org/library/papers/41026296 | PubMed |
| 40823339 | Refining Prognosis and Treatment Strategies Beyond the Barcelona Clinic Liver Cancer Stage in Hepatocellular Carcinoma with Lung Metastases: A Multicenter Cohort Study. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/40823339 | PubMed |
| 40682115 | SNRPB/CCNB1 axis promotes hepatocellular carcinoma progression and cisplatin resistance through enhancing lipid metabolism reprogramming. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40682115 | PubMed |
| 40636084 | Tumor burden score and alpha-fetoprotein level predict prognosis of patients with unresectable hepatocellular carcinoma treated with tyrosine kinase inhibitor and anti-PD-1 antibody. | ILIVER | 2024 | https://conductscience.org/library/papers/40636084 | PubMed |
| 40283886 | Preparation and Evaluation of Hepatoma-Targeting Glycyrrhetinic Acid Composite Micelles Loaded with Curcumin. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40283886 | PubMed |
| 39663164 | Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis. | BMJ Open | 2024 | https://conductscience.org/library/papers/39663164 | PubMed |
| 38997297 | Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma. | Cell Death Dis | 2024 | https://conductscience.org/library/papers/38997297 | PubMed |
| 38814517 | β-Sitosterol alleviates the malignant phenotype of hepatocellular carcinoma cells via inhibiting GSK3B expression. | Hum Cell | 2024 | https://conductscience.org/library/papers/38814517 | PubMed |
| 38399792 | How Possible Is the Elimination of Viral Hepatitis? An Analysis Based on the Global Burden of Disease from Hepatitis B and C, 1990-2019. | Microorganisms | 2024 | https://conductscience.org/library/papers/38399792 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| AFP | 174 | PubTator's text mining | https://conductscience.org/library/genes/174 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36924120
GET https://conductscience.org/api/papers/v1/36924120/references?page=2